MGB Biopharma Receives £1.3m Grant Award
Grant to help fund Phase I trial with lead candidate oral MGB-BP-3 for Clostridium difficile
13-Jun-2014 -
MGB Biopharma, a biopharmaceutical company developing truly novel anti-infectives, announced that it has been awarded a £1.3 million conditional grant from the Technology Strategy Board, the UK’s innovation agency, under its Biomedical Catalyst programme.
The grant will help fund a Phase I trial ...
anti-infectives
Clostridium difficile